The explanation for this phenomenon is based on a recently published article by Melo-Cardenas et al, in which the authors show that progression of myeloproliferative disorders is associated with increased IL-13 levels, whereas reductions in IL-4 and IL-13 are associated with reduced features of these disorders (19). Here, IL13 is linked to myeloproliferative disorder.